UBS Group
ZYBT

UBS Group’s Zhengye Biotechnology Holding ZYBT Stock Holding History

UBS Group’s Portfolio ZYBT Stock Details ZYBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.41K Sell
7,992
-44
-0.5% -$39 ﹤0.01% 8930
2026
Q1 		$7.51K Sell
8,036
-1,079
-12% -$1.01K ﹤0.01% 8569
2025
Q4 		$10.5K Buy
9,115
+4,786
+111% +$10.6K ﹤0.01% 8212
2025
Q3 		$11.3K Sell
4,329
-150,183
-97% -$1.04M ﹤0.01% 8493
2025
Q2 		$922K Buy
154,512
+153,223
+11,887% +$1.22M ﹤0.01% 5515
2025
Q1 		$6.93K Buy
+1,289
New +$5.99K ﹤0.01% 8869

Other funds holding ZYBT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

UBS Group's ZYBT Position: Q2 2026 in Review

UBS Group reduced its Zhengye Biotechnology Holding (ZYBT) stake by 0.55% in Q2 2026, selling an estimated $39 and leaving 7,992 shares worth $5.41K. The position accounts for ﹤0.01% of the portfolio, ranked #8930.

UBS Group first reported a position in ZYBT in Q1 2025 and has held it in 6 quarters since. The position peaked at $922K in Q2 2025. 6 funds tracked by Wall St. Rank hold ZYBT as of Q2 2026.

  • UBS Group held 7,992 shares of Zhengye Biotechnology Holding worth $5.41K as of Q2 2026.
  • UBS Group sold 44 Zhengye Biotechnology Holding shares in Q2 2026, an estimated $39.
  • Zhengye Biotechnology Holding made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8930 holding.
  • UBS Group first reported a position in Zhengye Biotechnology Holding in Q1 2025 and has held it in 6 quarters since.
  • UBS Group's Zhengye Biotechnology Holding position peaked at $922K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Zhengye Biotechnology Holding as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.